Drug recall · June 3, 2020
Lamotrigine Tablets recall
Why: Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Lamotrigine Tablets, USP, 150 mg, 20,000-count bulk container, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA, For repackaging by: AvKare Inc., Pulaski, TN 38478, Bulk Shipment, NDC 59746-247-97.
- Lots / codes
Lot #s 19P0437 & 19P0438, Exp. 09/30/2021.
- Quantity
- 1,313,333 tablets
- Company
- Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD
- Distribution
- TN
- Initiated
- May 26, 2020 · Voluntary: Firm initiated
- Classified
- May 29, 2020
- Reported
- June 3, 2020
- Ended
- November 15, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Lamotrigine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.